Trials / Terminated
TerminatedNCT04924413
L-TIL Plus Tislelizumab as First-line Treatment in Advanced Malignant Melanoma
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 9 (actual)
- Sponsor
- Quanli Gao · Other Government
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this study is to evaluate the safety and effectiveness of liquid tumor infiltrating lymphocytes (L-TIL) combined with tislelizumab as the first-line treatment in patients with advanced malignant melanoma. This study plan to include stage III or IV unresectable or metastatic cutaneous or acral malignant melanoma patients, treat with L-TIL 4 cycles with each infusion (3 -10) x10\*9/m2 cells, combined with tislelizumab 200mg, iv, Q3W. It is expected that 30 patients will be enrolled in this study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tislelizumab | PD-1 positive lymphocytes are isolated from peripheral blood and amplified for transfusion |
Timeline
- Start date
- 2021-07-01
- Primary completion
- 2024-07-02
- Completion
- 2024-07-02
- First posted
- 2021-06-14
- Last updated
- 2024-07-03
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04924413. Inclusion in this directory is not an endorsement.